linoleic-acid and Heart-Diseases

The capacity of an oil, containing gamma-linolenic acid (GLA), to reduce the severity of doxorubicin-induced cardiotoxicity has been investigated in a rat model. Groups of 12-week-old, male, Sprague-Dawley rats were injected intravenously (i.v.) with single doses (3 mg/kg body weight) of doxorubicin (DOX). Daily for 1 week prior to DOX administration and for up to 20 weeks afterwards groups of rats received either an oil containing both GLA and linoleic acid (So-1100, Scotia Pharmaceuticals), at two dose levels, or an oil containing linoleic acid, but no GLA (So-1129) by oral gavage. Other groups of rats received water as a control. One of the groups of rats that received water also received i.v. ICRF-187 (60 mg/kg) 15 min prior to DOX. A group of animals acted as age-matched controls. The maximum reduction in body weight in the first 2 weeks after the administration of DOX. was used as a measure of acute toxicity. This was most severe in the group receiving a combination of DOX and ICRF-187 (5.6+/-0.43%). Animals receiving 2 ml of either So-1100 or So-1129 were the least affected ( approximately 2.5%). Measurements of cardiac volume output made at various intervals after DOX administration indicated a approximately 35% reduction in cardiac function in the control and So-1129 oil group after 20 weeks. The corresponding reduction in the groups receiving ICRF-187 and 2 ml of So-1100 was approximately 16%. The group receiving daily doses of 1 ml So-1100 showed an intermediate response. The death of an animal with signs of congestive cardiac failure occurred in 40% of the animals in the DOX only control (water) group. There were no deaths in the groups of rats receiving either ICRF-187 or pre- and post-administration of 2 ml of So-1100. It was concluded that an oil containing GLA (So-1100) has similar cardioprotective properties against DOX-induced cardiotoxicity as ICRF-187, but with less general toxicity in this rat model.

Topics: Animals; Antineoplastic Agents; Doxorubicin; gamma-Linolenic Acid; Heart Diseases; Linoleic Acid; Male; Rats; Rats, Sprague-Dawley; Razoxane; Weight Loss

For 16 wk Atlantic salmon (Salmo salar) post-smolts were fed practical-type diets that contained either fish oil (FO) or sunflower oil (SO) as the lipid component. Both diets contained adequate (n-3) polyunsaturated fatty acids (PUFA). All the phospholipids of heart and liver from SO-fed fish had increased levels of 18:2(n-6), 20:2(n-6) and 20:3(n-6); phosphatidyl choline (PC) and phosphatidyl ethanolamine (PE) also had increased 20:4(n-6). There was a general decrease in 20:5(n-3) in the phospholipids, reflected in an increase in the 20:4(n-6)/20:5(n-3) ratio, especially in PC and PE. The fatty acid compositions of phospholipids from brain and retina were much less affected by dietary linoleate than those of heart and liver. Fish fed SO developed severe heart lesions that caused thinning of the ventricular wall and muscle necrosis. The fish fed SO also were susceptible to a transportation-induced shock syndrome that caused 30% mortality. These results establish that a diet with a low (n-3)/(n-6) ratio can cause changes in fatty acid metabolism that are deleterious to the health of salmonid fish, especially when subjected to stress.

Topics: Animals; Brain; Dietary Fats, Unsaturated; Fatty Acids; Fish Oils; Heart; Heart Diseases; Linoleic Acid; Linoleic Acids; Liver; Myocardium; Necrosis; Phosphatidylcholines; Phosphatidylethanolamines; Phospholipids; Plant Oils; Retina; Salmon; Stress, Physiological; Sunflower Oil

Topics: Carbon Isotopes; Fatty Acids; Glycerides; Heart Diseases; Hyperlipidemias; Hypertriglyceridemia; Linoleic Acid; Lipid Metabolism; Lipids; Lipoproteins; Myocardial Infarction; Palmitates; Palmitic Acid; Tritium